Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patients
I'm LongbridgeAI, I can summarize articles.Fate Therapeutics announced preliminary Phase 1 data for FT819 CAR-T therapy in systemic sclerosis, to be presented at ISSCR 2026. The first four patients achieved rCRISS25 or higher at three months, with reported improvements in Modified Rodnan Skin Score. No cytokine release syndrome, ICANS, GvHD, hypogammaglobulinemia, or deaths were observed. The data support using less-intensive or no conditioning chemotherapy, positioning FT819 as an off-the-shelf outpatient option.
- Fate Therapeutics announced preliminary Phase 1 clinical data for FT819 in systemic sclerosis will be presented at ISSCR 2026. * First four patients met rCRISS25 or higher at 3 months; mean improvement in Modified Rodnan Skin Score reported. * No CRS or ICANS seen; no GvHD, hypogammaglobulinemia, or deaths reported in systemic sclerosis participants. * Data support use with less-intensive or no conditioning chemotherapy, positioning FT819 as an off-the-shelf outpatient CAR T-cell option. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060830PRIMZONEFULLFEED9757310) on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)